Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term observational follow-up after phase III trial of dicyclol for acute drug-induced liver injury
ChiCTR2300072274Phase 3Not yet recruiting
- Sponsor
- Renji Hospital
- Start
- Apr 2023
- Countries
- 1
01
Overview
Phase 3, open-label trial of dicyclol in Drug-induced hepatitis (DILI) (2 arms), sponsored by Renji Hospital. Primary endpoint: Composite outcome events at week 20. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
dicyclol
03
Conditions
Drug-induced hepatitis (DILI)
Beyond the preview
Go deeper on ChiCTR2300072274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072274.